Spruce Biosciences Receivables 2020-2025 | SPRB

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Spruce Biosciences receivables from 2020 to 2025. Receivables can be defined as the total amount of collectibles for a company

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Spruce Biosciences receivables from 2020 to 2025. Receivables can be defined as the total amount of collectibles for a company

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$228.5B
Amgen (AMGN)	$165.9B
Gilead Sciences (GILD)	$140.8B
Vertex Pharmaceuticals (VRTX)	$121.3B
Bristol Myers Squibb (BMY)	$99.6B
CSL (CSLLY)	$86.2B
GSK (GSK)	$78.3B
Regeneron Pharmaceuticals (REGN)	$61B
Alnylam Pharmaceuticals (ALNY)	$42.8B
Argenex SE (ARGX)	$36.2B
BioNTech SE (BNTX)	$27.5B
Royalty Pharma (RPRX)	$20.6B
Insmed (INSM)	$19.6B
Biogen (BIIB)	$19.4B
Illumina (ILMN)	$17B
Genmab (GMAB)	$15.2B
Genmab (GNMSF)	$14.9B
Incyte (INCY)	$13.6B
Moderna (MRNA)	$13.2B
Exelixis (EXEL)	$12.2B
BioMarin Pharmaceutical (BMRN)	$11.5B
QIAGEN (QGEN)	$11.4B
Swedish Orphan Biovitrum (BIOVF)	$10.6B
Ascendis Pharma (ASND)	$10.3B
Exact Sciences (EXAS)	$9.2B
Bio-Techne Corp (TECH)	$9.2B
Verona Pharma American Depositary Share (VRNA)	$8.9B
Blueprint Medicines (BPMC)	$8.3B
Legend Biotech (LEGN)	$8.1B
Roivant Sciences (ROIV)	$7.7B